Table 4.
Pre-treatment M (SD) | Post-treatment M (SD) | 3-month follow-up M (SD) | F(df) | P | Partial eta-squared | |
---|---|---|---|---|---|---|
Primary outcome | ||||||
PHQ-9 | 14.4 (5.39) | 6.33 (4.90) | 6.75 (6.11) | 19.4(2) | <.001 | 0.734 |
Secondary outcome | ||||||
GAD-7 | 7.89 (5.23) | 3.56 (3.75) | 4.50 (3.82) | 8.44(2) | 0.004 | 0.547 |
Repeated Measures ANVOA With Missing 3-Month Follow-Up Data for One Participant Imputed With Their Baseline Symptom Scores (N = 9). | ||||||
Pre-treatment M (SD) | Post-treatment M (SD) | 3-month follow-up M (SD) | F(df) | P | Partial eta-squared | |
Primary outcome | ||||||
PHQ-9 | 14.4 (5.39) | 6.33 (4.90) | 8.00 (6.84) | 17.7(2) | <.001 | 0.689 |
Secondary outcome | ||||||
GAD-7 | 7.89 (5.23) | 3.56 (3.75) | 4.67 (3.61) | 5.23(2) | 0.018 | 0.395 |